Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication 1. INDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. FDA label
Ivabradine · 1 trial · 1 indication
Orthostatic heart rate monitoring will be used to gauge heart rate changes.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Patient will consume one placebo pill twice a day for one month. |
| Ivabradine | EXPERIMENTAL | Patient will consume one dose of Ivabradine twice a day for one month. |
| Name | Type | Description |
|---|---|---|
| Ivabradine | DRUG | Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node. |
| Placebo | DRUG | A substance that has no therapeutic effect and will act as a control. |
Inclusion Criteria: * Subjects aged 18-65. * Subjects must have POTS diagnosis (Hyperadrenergic Subtype with NE\> 600pg/ml)) * Subjects with no structural heart disease * Subject with no arrhythmias * Subjects with norepinephrine levels greater than 600 pg/ml * Subjects with normal CBC, Metabolic, ...
Ivabradine is being studied as a treatment for Postural Orthostatic Tachycardia Syndrome, a condition marked by an abnormally rapid heart rate upon standing. It is an investigational therapy in this indication and has been evaluated in a Phase 3 clinical trial. Ivabradine is developed by Amgen Inc.
Ivabradine targets HCN4, a hyperpolarization-activated cyclic nucleotide-gated channel that helps regulate the heart's pacemaker current. By blocking HCN4, ivabradine reduces heart rate without affecting other cardiac functions. This mechanism underlies its investigation for Postural Orthostatic Tachycardia Syndrome.
Amgen Inc. (ticker: AMGN) is the developer of ivabradine for Postural Orthostatic Tachycardia Syndrome. Amgen is a biopharmaceutical company focused on cardiovascular and other therapeutic areas.
Ivabradine is in Phase 3 development for Postural Orthostatic Tachycardia Syndrome. It is an investigational small molecule and has not been approved for this indication. The Phase 3 trial has been completed.
Ivabradine has been studied in a Phase 3 clinical trial for Postural Orthostatic Tachycardia Syndrome: NCT03182725, titled "Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome." The trial was completed, enrolled 37 participants, and was randomized, double-blind, and placebo-controlled.